Metabotropic glutamate receptor 2 (mGluR2)

Metabotropic glutamate receptor 2 is a class C G protein-coupled receptor encoded by the GRM2 gene. It is primarily expressed in neurons and astrocytes within the human brain. Functionally, it acts as an autoreceptor at presynaptic terminals where its activation inhibits vesicular release of neurotransmitters—mainly through inhibition of presynaptic calcium channels—thereby modulating synaptic transmission and neuronal excitability. The receptor plays a key role in regulating central nervous system activity and has been implicated as a therapeutic target for several neuropsychiatric conditions including schizophrenia, depression, anxiety disorders, Parkinson’s disease, Alzheimer’s disease, pain states (especially chronic pain), and drug addiction. Pharmacologically relevant ligands include orthosteric agonists such as L-glutamate and synthetic compounds like LY354740; positive allosteric modulators are under investigation for their potential therapeutic benefits with improved selectivity profiles. Safety concerns relate mainly to CNS side effects due to widespread expression and challenges with achieving high subtype specificity over other group II metabotropic glutamate receptors.

Other names

GRM2GPRC1BMGLUR2mGlu2glutamate metabotropic receptor 2GLUR2

– Orthosteric agonists activate the receptor by binding to the extracellular ligand-binding domain. – Positive allosteric modulators enhance the response to endogenous glutamate without directly activating the receptor. – Antagonists inhibit activation by blocking ligand binding or downstream signaling.